Since the crisis began, Orchard has been researching the industry to be able to provide a trusted solution in combating the spread of this crisis. On March 13, 2020, the United States (US) Food and Drug Administration (FDA) issued Emergency Use Authorization (EUA) for a testing solution utilizing a new multiplex Real-Time-Polymerase Chain Reaction (RT-PCR) diagnostic kit to enable clinical and public health laboratories to quickly diagnose COVID-19 caused by SARS-CoV-2 infection.
In response to the current coronavirus pandemic, Orchard Laboratories has worked rapidly to secure the most modern equipment to provide the medical community this newly introduced (under FDA EUA criteria) multiplex RT-PCR diagnostic kit. Our mission is to enable clinical professionals to quickly diagnose COVID-19 caused by SARS-CoV-2 infection.
Orchard Laboratories is one of the first to receive this type of testing equipment in Michigan and has ramped up its laboratory capabilities to comply with the specific regulations.
Orchard is here to assist in stopping this pandemic by slowing down the spread. Testing allows those who have contracted the virus to be treated, to isolate, and to stop the spread